[1] 杨运高,陈先明,王学良,等.活血化瘀代表方药抗肿瘤转移的实验研究.生命科学研究[M].北京,科学技术出版社,2003:409. [2] 许勤,吴文溪.小鼠结肠腺癌肝转移模型的建立[J].实用癌症杂志(J Prac Oncol),2000,15(5):456-7. [3] Fromowitz FB, Viola MV, Chao S, et al. Ras P21 expression in the progression of breast cancer [J]. Human Pathol, 1987, 18: 1268-675. [4] 孙惠川.癌转移研究协会第八届国际会议简介[J].国外医学·肿瘤学分册(Foreig Med·Oncol Sec),1999,26(4):204. [5] Stangl R, Altendorf-Hofmann A, Charnley RM, et al. Factors influencing the natural history of coloreatal liver metastases [J]. Lancet,1994, 343(6): 1405-1210. [6] Kim NW, Piatszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cell and cancer[J]. Science,1994, 266(23): 2001-15. [7] 卫建平,张波.端粒酶HTR和hTERT在肿瘤中的表达及意义[J].临床与实验病理学杂志(J Clin Exp Pathol),2002,18(2):156-8. [8] Lane DP. P53 guardian of the genome[J]. Nature, 1992(1): 358. [9] Brunt EM, Swanson PE. Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver[J]. Am J Clin Pathol,1992(suppl 1): s53. [10] Yam aguchi S, Ohki S, Jo T, et al. Expression of c-erbB-s protein and vessel invasion in colorectal cancer[J]. Gan To Kagaku Ryoho,1992, 19(1): 34. [11] Manne U, Weiss HL, Grizzle WE. BCL-2 expressions associated with improved prognosis in patients with distal colorectal adenocar cinomas[J]. Int J Cancer, 2000, 89(5): 423-30. |